A Real-World Assessment of the demographic, clinical characteristics and outcomes of a Brazilian cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer receiving Durvalumab combined with Platinum-Etoposide in (ES-SCLC) in Brazil

Trial Identifier: D4191R00053
Sponsor: AstraZeneca
Collaborator:
AstraZeneca
NCTID:: NCT06008353
Start Date: January 2024
Primary Completion Date: August 2026
Study Completion Date: August 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil, Bahia Salvador, Bahia, Brazil, 41.950-640
Brazil, Pernambuco Recife, Pernambuco, Brazil, 50.070-480
Brazil, Rio de Janeiro Rio De Janeiro, Rio de Janeiro, Brazil, 22.281-100
Brazil, S�o Paulo S�o Paulo, Brazil, 01.509-001
Brazil, S�o Paulo S�o Paulo, Brazil, 01.323-030